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Abstract
Background: Previous studies of brain and peripheral tissues in schizophrenia patients have indicated impaired energy
supply to the brain. A number of studies have also demonstrated dysfunction of the microvasculature in schizophrenia
patients. Together these findings are consistent with a hypothesis of blood-brain barrier dysfunction in schizophrenia. In
this study, we have investigated the cerebral vascular endothelium of schizophrenia patients at the level of transcriptomics.
Methodology/Principal Findings: We used laser capture microdissection to isolate both microvascular endothelial cells and
neurons from post mortem brain tissue from schizophrenia patients and healthy controls. RNA was isolated from these cell
populations, amplified, and analysed using two independent microarray platforms, Affymetrix HG133plus2.0 GeneChips and
CodeLink Whole Human Genome arrays. In the first instance, we used the dataset to compare the neuronal and endothelial
data, in order to demonstrate that the predicted differences between cell types could be detected using this methodology.
We then compared neuronal and endothelial data separately between schizophrenic subjects and controls. Analysis of the
endothelial samples showed differences in gene expression between schizophrenics and controls which were reproducible
in a second microarray platform. Functional profiling revealed that these changes were primarily found in genes relating to
inflammatory processes.
Conclusions/Significance: This study provides preliminary evidence of molecular alterations of the cerebral microvascu-
lature in schizophrenia patients, suggestive of a hypo-inflammatory state in this tissue type. Further investigation of the
blood-brain barrier in schizophrenia is warranted.
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Introduction
Despite decades of research and numerous competing hypoth-
eses, our understanding of the pathophysiology of schizophrenia
remains unclear, with adverse consequences for both diagnosis and
treatment. In recent years an increasing body of evidence has
pointed towards altered glucose metabolism in schizophrenic
patients. In addition to the major findings of hypofrontality in
patients obtained using brain imaging methods [1], numerous post
mortem studies have shown alterations in the expression of genes
and proteins involved in major energy metabolism pathways [2–
6], and studies of peripheral tissues have also detected metabolic
alterations in first onset and drug naı ¨ve patients [7,8]. Examina-
tion of these data suggests an abnormality in glucose utilization in
the brains of patients which may arise from impaired supply of
energy substrates such as glucose and lactate [5,7]. Such findings
are consistent with an hypothesis of blood-brain barrier impair-
ment in schizophrenia [9]. This hypothesis proposes that
disruption in the coupling of cerebral blood flow to neuronal
metabolic needs may be upstream of all conceivable functional
neuronal abnormalities in schizophrenia.
A small but growing body of evidence points towards
dysfunction of the microvasculature in schizophrenia. The niacin
skin flush response has been widely reported to be abnormal in
schizophrenic patients [10–14] and may be explained by
abnormal vasodilatation. Furthermore, some studies have shown
a decreased resting cerebral blood flow [15,16] and decreased
cerebral vascular volume in schizophrenic patients [17], with other
data suggesting an increase in blood volume in certain brain
regions [18], consistent with abnormalities of the cerebral
microvasculature. A recent stereological study of capillary length
density in schizophrenia brain tissue failed to find differences
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reconcile these two apparently conflicting findings by proposing
dysfunction of the cerebral microvasculature at a molecular, rather
than structural level. However, few if any molecular studies of the
cerebral vasculature in schizophrenia have been attempted, and
existing quantitative molecular studies based on tissue homogenate
or sections are unlikely to include a signal from the relevant cells as
vasculature accounts for only 0.1% of whole brain tissue [20].
In this study we have attempted to characterise the cerebral
microvasculature of schizophrenia patients by using laser micro-
dissection to isolate cells from post mortem prefrontal cortex tissue.
Laser microdissection has been widely touted as a major advance
in molecular brain research [21], but has rarely [2,22] been
applied to the human postmortem brain due to the technical
challenges raised by working with small amounts of tissue and the
variability that may be introduced at various stages of the
analytical process. Thus as a first step to check the integrity of the
data, we compared data from endothelial cells to data from
neurons in order to demonstrate whether the predicted differences
between these two cells types could be detected. We then
proceeded to investigate gene expression differences in these cell
types in schizophrenia using microarrays. Although microarray
technology has been demonstrated to be robust and reproducible
in careful hands, validation of the results at the technical level is
essential to increase confidence in a study. Quantitative real-time
PCR, the most commonly used validation tool, is limited in that
only a small number of genes can practically be measured within a
single study, and the necessity to normalize to a so-called
‘‘housekeeping’’ gene introduces high levels of experimental noise.
Thus in the present study we have taken the approach of using two
array platforms, each possessing different probe design, synthesis
and attachment strategies and different hybridization kinetics and
lab procedure. Using this approach not only can mRNA levels be
validated, but also differences in microarray methodology,
normalization and data processing methods.
Methods
Tissue collection
Consent: Human brain tissue was obtained from the Array
collection of the Stanley Medical Research Institute (Bethesda,
USA). Tissue was collected post mortem from patients and controls
with full informed consent obtained from a first degree relative
after death in compliance with the Declaration of Helsinki. The
consent was obtained by questionnaires conducted over the phone
and signed by two witnesses. All patient data are anonymised.
Exemption from IRB approval was granted by the Uniformed
Services University of Health Sciences IRB on the grounds that
specimens were obtained via informed donation from cadaveric
material in accordance with federal and state regulations, the
research did not encompass genetic linkage studies, and all
samples were de-identified and personal information anonymised.
Fresh-frozen gray matter tissue from dorsolateral prefrontal
cortex (Brodmann area 9) of 12 schizophrenia patients and 12
matched control individuals was used in the study. The cell type
analysis also included 12 subjects with bipolar disorder (see
Supplementary Information S1).
Laser capture microdissection
Cells were visualised using a rapid fluorescence immunostaining
method designed for optimal RNA preservation. Examples of
immunostaining are shown in Fig 1. 15 mm tissue sections were cut
onto polyethylene naphthalate membrane slides (Zeiss) and fixed
for 10 minutes in acetone. After air drying, sections were
incubated with either rabbit anti-von Willebrand factor (Chemi-
con) or mouse anti-neurofilament-160/200 kD (Cambridge Bio-
science) for 5 minutes, followed by brief washing in RNase-free
phosphate buffered saline (PBS) and incubation in secondary
antibody for 5 minutes (Cy3-conjugated goat anti-rabbit IgG or
Cy2-conjugated goat anti-mouse IgG (Jackson Immunoresearch).
All antibodies were used at 1:20 dilution with 1 unit/ml RNase
inhibitor (GE Healthcare) in RNase-free PBS (Ambion). These
incubation conditions were found to give the best staining for cell
identification together with optimal RNA preservation. Following
antibody incubation and brief washing in PBS, sections were then
dehydrated through ethanol series and cell capture was initiated
immediately. Laser capture microdissection was carried out using
the PALM microlaser system [23]. 1000 neurons were captured
from each subject, in two batches of 500, or an equivalent area of
vascular endothelium (approximately 40 0000 mm2). Pyramidal
neurons were selected based on staining and morphology.
Following capture, RNA was extracted from cells using the
Figure 1. Examples of fluorescence immunostaining. A rapid immunostaining method was developed to identify endothelial cells (A–D) and
neurons (E–H) in human prefrontal cortex tissue, whilst maintaining optimal RNA preservation. (A, E) low power (610) images of cell staining in prefrontal
cortex tissue; (B, F) high power (640) image of cells before capture; (C, G) cells selected ready for capture (D, H) tissue sections post-capture.
doi:10.1371/journal.pone.0003964.g001
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using the RiboAmp HS kit (Arcturus). The resulting aRNA was
assessed on an Agilent Bioanalyser Nanochip to determine length
of RNA transcripts in the samples. aRNA profiles with jagged
curves or pronounced skews to the left, indicating degradation of
the RNA, were eliminated from the analysis.
Microarray hybridisation
Amplified RNA was converted to cDNA using Round 2
components of the RiboAmp HS kit, labelled by in vitro
transcription in the presence of biotinylated UTP (Codelink
Expression Assay kit, GE Healthcare), and purified using YM-30
columns (Microcon).
Labelled RNA was hybridised to both Affymetrix and Codelink
chips according to manufacturers’ recommendations. Balanced
numbers of patient and control samples were included in each
hybridisation batch.
Data analysis
All datasets (endothelial and neuronal, disease and control
samples) were subjected to normalisation and quality control
measures together, within each array platform. Only samples
which passed quality control on both platforms were included in
the final dataset, to facilitate cross-platform validation. An outline
of the data analysis workflow is shown in Fig 2.
Affymetrix arrays
Datapre-processing. Qualitycontrol protocolsfor Affymetrix
microarray data derived from human postmortem brains were
applied as previously described [24], and samples which did not pass
were removed from the dataset. Expression measures were
computed for each of the probesets on each of the GeneChips in
the dataset using the robust multichip average (RMA) method [25],
which is implemented in the BioConductor package ‘Affy’ [26]. The
‘Affy’ package was also used to generate RNA digestion plots which
allow any 59 to 39 trend to be visualized. A linear regression of
expression values on the logarithm (base 2) of slope of the RNA
digestion plots for each probeset was performed and the residuals
from the regression were assigned as expression values for further
analysis. This transformation effectively corrected for any systematic
error in the data introduced by 39 signal bias and significantly
improved the quality of the data (see Supplementary Information
S1). Following transformation, all 54647 probes were included in the
analysis. The data have been submitted to GEO (www.ncbi.nlm.nih.
gov/geo/), accession numbers GSM318410-GSM318441; series
record GSE12679.
Demographics. Demographic variables for the disease-based
analysis are shown in Tables 1 & 2. No significant differences
between patients and controls were found for pH, PMI or age in
either cell type. The distribution of demographic variables for the
cell-type analysis can be found in Supplementary Information S1.
LIMMA. A Bayesian moderated t-test was applied to identify
differentially expressed genes as implemented in the LIMMA
(linear models for microarray analysis) package [27] from
Bioconductor. Firstly, pre-processed Affymetrix datasets were
collapsed to the probeset with the maximum expression value
for each gene using the Gene Set Enrichment Analysis software
(details below). Differentially expressed genes were then identified
using the LIMMA package and raw p-values were adjusted for
multiple hypothesis testing using the false discovery rate (FDR)
method of Benjamini and Hochberg [28].
Functional profiling. Two complimentary approaches to
gene set analysis were employed. Both methods investigated all
Figure 2. Diagram showing overview of experimental workflow.
doi:10.1371/journal.pone.0003964.g002
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consortium (GO). The default GSEA significance threshold of
q,0.25 (after controlling the false discovery rate) was used for all
functional analyses.
GSEA. The GSEA algorithm examines a ranked list of all
genes on the chip, and identifies whether members of a gene
category are enriched at either the top or bottom, using a modified
Kolmogorov-Smirnov statistic. GSEA was carried out following
the recommendations of the authors [29,30]. Pre-processed
expression data was inputted to the GSEA software and
collapsed to the probe with the maximum expression level for
each gene prior to analysis. Genes were ranked by fold change
calculated using the ‘‘difference of class means’’ metric
implemented in the GSEA software, such that genes ranked
towards the top of the list are considered enriched in one sample
group and genes ranked at the bottom are considered enriched in
the other. Enrichment scores were calculated using the weighted
enrichment statistic, and significance levels calculated by
permuting phenotype labels 1000 times. Gene set size filters
were set to exclude gene sets containing fewer than 25, or greater
than 500 members. All other parameters were set to GSEA
defaults.
In the schizophrenia versus control analysis the gene sets
investigated comprised the complete list of human biological
process categories present on the U133 Plus 2.0 array as defined
by the GO consortium (subject to filters as described above;
around 3000 categories in total). Some categories represent closely
related functions and in addition, multifunctional genes may be
annotated in more than one category. GSEA examines each gene
set independently and hence multiple categories annotated to the
same or similar genes can arise due to the hierarchical nature of
the GO database. We therefore used the leading edge analysis tool
within GSEA to identify related sets, i.e. those in which the
significance is driven by an overlapping subset of genes (the
‘‘leading edge’’).
OntoExpress. The OntoExpress software uses an algorithm
which examines a predetermined list of significant genes and
identifies categories of genes which are over or under represented
in this list relative to their representation on the entire chip.
Following LIMMA analysis genes were ranked in order of t
statistic. A list of the top 2% of genes most significantly up- and
down-regulated (this included 402 genes from the Affymetrix
dataset corresponding to a p value cutoff of 0.027 among the
upregulated genes and 0.047 among the downregulated genes)
were analysed separately using OntoExpress, using default settings
(hypergeometric distribution and FDR (Benjamini-Hochberg)
correction) and the Affymetrix human HG-U133 Plus 2.0 array
as reference. Categories which had at least 3 members were
considered in the analysis.
Codelink arrays
Data preprocessing. Image analysis and feature extraction
was performed using the proprietary Amersham CodeLink
Bioarray software (GE Healthcare). A flag-based noise filter was
applied such that probes were retained for further analysis which
had a ‘‘good’’ flag in a minimum number of arrays corresponding
to the smallest sample group tested (eg where there were 12
control and 12 schizophrenia samples, the filter was set to retain
Table 1. Endothelial sample demographics.
Group (n) Control (7) Schizophrenia (9) p value
Age (yrs; mean6SD) 42.767.8 43.2610.6 0.917
Gender (n; F/M) 1/6 3/6 n/a
pH (mean6SD) 6.660.2 6.560.3 0.363
PMI (hours; mean6SD) 20.3610.4 29.6610.1 0.094
Diagnosis (n; paranoid/undifferentiated) n/a 2/7 n/a
Medicated at TOD (n; yes/no) 0 8/1 n/a
Lifetime medication (fluphenazine mg equiv; mean6SD) 0 1128386154662 n/a
Demographic variables for endothelial samples included in the disease-based analysis (F: female; M: male; PMI: post mortem interval; SD: standard deviation; TOD: time
of death).
doi:10.1371/journal.pone.0003964.t001
Table 2. Neuronal sample demographics.
Group (n) Control (6) Schizophrenia (5) p value
Age (yrs; mean6SD) 41.267.2 45.065.4 0.353
Gender (n; F/M) 2/4 2/3 n/a
pH (mean6SD) 6.660.2 6.660.1 0.682
PMI (hours; mean6SD) 30.0618.6 28.467.9 0.862
Diagnosis (n; paranoid/undifferentiated) n/a 1/4 n/a
Medicated at TOD (n; yes/no) 0 4/1 n/a
Lifetime medication (fluphenazine mg equiv; mean6SD) 0 44010635056 n/a
Demographic variables for neuronal samples included in the disease-based analysis (F: female; M: male; PMI: post mortem interval; SD: standard deviation; TOD: time of
death).
doi:10.1371/journal.pone.0003964.t002
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was carried out independently for the cell-type and disease
analyses. The spot mean signal intensities for probes passing the
filter were quantile normalized [31] to generate gene expression
measures. Outlier removal was carried out based on a correlation
matrix generated from all possible pairwise comparisons between
arrays using Pearson’s product-moment correlation coefficient as
the metric. Poorly correlating arrays were removed from the
analysis. After removing outliers, the flag-based noise filter and
normalisation process were re-applied. The final dataset for the
cell type analysis (all samples) contained 10487 probes. For the
disease-based analysis endothelial and neuronal samples were
normalised separately and the final dataset contained 8846 probes
for the endothelial samples and 14262 probes for the neuronal
samples. Due to the much reduced number of probes on the
Codelink arrays compared to the Affymetrix arrays, Codelink
arrays were used solely for validation purposes and not for the
primary analysis.
Cross platform validation
Data were cross-validated between array platforms using GSEA
and the method of Cheadle et al (2006) [32]. This method was
developed to examine the entire dataset, taking into account the
differences in absolute mRNA quantitation which often occur
between array platforms. Following one microarray analysis, the
most significantly altered genes are used to create a category. Data
from an alternative microarray platform are then probed with this
category. If the data are reproducible in the second platform, the
category should be significantly enriched in the predicted
direction. Datasets were collapsed to the maximum probe level
per gene using GSEA, filtered to those genes which were present
across both platforms and ranked using the GSEA metric
‘‘difference of class means’’. The 200 top and bottom ranking
genes from each array platform were each used to create a gene
set. We then determined whether the top ranking genes from each
platform showed enrichment in the same direction in the other
platform, using the GSEA parameters described above.
Results
Cell type analysis
As an initial assessment of the biological validity of the data, we
compiled a list of biological processes, as defined by the Gene
Ontology Consortium, likely to be specific to one cell type or the
other, using the search terms ‘‘neuron’’, ’’neurotransmitter’’ and
‘‘synapse’’ plus ‘‘endothelial’’, and ‘‘angiogenesis’’. Due to the
small number of categories found to be endothelial-related, we also
included cell proliferation as an endothelial-related category, as
there is no published evidence for neurogenesis in the adult
prefrontal cortex [33]. These categories were tested for enrich-
ment in the Affymetrix data using GSEA. All endothelial
categories were found to be significantly enriched in the
endothelial data, and all neuronal categories were found to be
significantly enriched in the neuronal data (q,0.25; Table 3).
Additionally we chose a panel of six genes expected from the
literature to be preferentially expressed in one cell type or the
other in brain tissue, and investigated whether these were found
differentially expressed between cell types using our methods. In
the Affymetrix dataset, all six genes considered to differentiate
endothelial cells from neurons (fibronectin (FN1), osteonectin
(SPARC), integrin alpha5 (ITGAV), vascular endothelial cadherin
(CDH5), endothelial PAS domain protein 1 (EPAS1), gap junction
protein alpha4 (GJA4)) were significantly upregulated in our
endothelial cell samples, and all six of those chosen to be neuronal
differentiators (neural cell adhesion molecule L1 (L1CAM),
synaptosomal protein 25 (SNAP25), synaptophysin (SYP), voltage
gated sodium channel type IIIbeta (SCN3B), vesicular glutamate
transporter (SLC17A7), Thy-1 cell surface antigen (THY1)) were
significantly upregulated in our neuronal samples (Fig 3, Table 4).
Furthermore, we examined the expression of markers of other cell
types: GFAP, an astrocyte marker, and CNP, a marker of
oligodendrocytes. These genes showed low expression values, and
did not show differential expression between cell types. The
method of Cheadle et al [32] was used to cross validate the entire
dataset between chip platforms. In all cases both platforms
reflected similar changes for genes with the greatest differential
Table 3. Results of cell type comparison–gene categories.
GO ID Category Name Cell type NES FDR q value
GO:0001525 angiogenesis E 1.49 0.028
GO:0008283 cell proliferation E 1.51 0.037
GO:0045765 regulation of angiogenesis E 1.40 0.046
GO:0048666 neuron development N 21.42 0.055
GO:0030182 neuron differentiation N 21.43 0.060
GO:0019226 transmission of nerve impulse N 21.45 0.061
GO:0048699 generation of neurons N 21.45 0.075
GO:0048667 neuron morphogenesis during differentiation N 21.46 0.092
GO:0007269 neurotransmitter secretion N 21.56 0.093
GO:0007268 synaptic transmission N 21.48 0.118
GO:0042551 neuron maturation N 21.23 0.166
GO:0001505 regulation of neurotransmitter levels N 21.26 0.169
GO:0050808 synapse organization and biogenesis N 21.24 0.173
GO:0006836 neurotransmitter transport N 21.13 0.241
GSEA results for categories characteristic of either endothelial cells (E) or neurons (N). Positive normalized enrichment scores (NES) indicate categories enriched in
endothelial samples, negative NES indicate categories enriched in neuronal categories. All endothelial categories showed significant enrichment in the endothelial
samples and all neuronal categories showed significant enrichment in the neuronal samples (q,0.25).
doi:10.1371/journal.pone.0003964.t003
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PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e3964Figure 3. Characteristic endothelial and neuronal genes. Boxplots showing the expression levels (arbitrary units, derived from Affymetrix
Genechips) in endothelial (red) and neuronal (blue) samples of a panel of genes known to be preferentially expressed in either (a) endothelial cells or
(b) neurons in brain tissue, plus (c) two markers known to be expressed in other cell types.
doi:10.1371/journal.pone.0003964.g003
Table 4. Results of cell type comparison–individual genes.
Gene symbol Gene name Cell type Affymetrix Codelink
Fold change q value Fold change q value
EPAS1 Endothelial PAS domain protein 1 E 3.09 ,0.0001 0.93 0.5568
GJA4 Gap junction protein alpha4 E 1.62 0.0116 1.18 0.0645
ITGAV Integrin alpha5 E 2.95 ,0.0001 Not detected
SPARC Osteonectin E 1.87 0.0012 1.56 0.0003
CDH5 Vascular endothelial cadherin E 1.24 0.0124 Not detected
FN1 Fibronectin E 2.36 ,0.0001 1.99 ,0.0001
L1CAM Neural cell adhesion molecule L1 N 21.84 0.0001 Not detected
THY1 Thy-1 cell surface antigen N 22.94 ,0.0001 21.99 0.0045
SCN3B Voltage gated sodium channel type IIIbeta N 23.04 ,0.0001 Not detected
SLC17A7 Vesicular glutamate transporter N 23.14 ,0.0001 21.32 0.0011
SNAP25 Synaptosomal protein 25 N 22.75 0.0007 21.32 0.0423
SYP Synaptophysin N 21.54 0.0121 21.20 0.0009
GFAP Glial fibrillary acidic protein A 1.22 0.4727 Not detected
CNP 29,39-cyclic nucleotide 39 phosphodiesterase O 21.07 0.8321 Not detected
Differential expression of genes previously shown to be preferentially expressed in neurons (N), endothelial cells (E), astrocytes (A), or oligodendrocytes. Fold changes
are calculated as endothelial cells relative to neurons. Of the genes which were present across both array platforms, only EPAS1 was not significant in both.
doi:10.1371/journal.pone.0003964.t004
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Furthermore, four of each of the neuronal and endothelial
markers were also detected in the Codelink dataset; only one
failed to cross validate between datasets (Table 4).
Having established that biologically valid differences between
cell types could be detected in the dataset, we moved on to
investigate whether differences could be detected between
schizophrenia patients and controls in either cell type. LIMMA
analysis revealed 1156 genes significantly differentially expressed
in endothelial cells and 803 in neurons at p,0.05; however, when
correction for multiple hypothesis testing was applied, no genes
reached significance. This is likely to be explained by the small
sample number and relative subtlety of the expected disease-
related changes. In order to determine whether the disease signal
could be validated using an alternative methodology, we applied
the method of Cheadle et al [32] to validate across chip platforms.
In the endothelial dataset, a set of genes whose expression was the
most different between schizophrenia and control on one chip
platform were found to be significantly enriched in the predicted
direction on the other platform (Table 6, Fig 4), suggesting that a
reproducible disease signal could be detected in the endothelial
samples. However, in the neuronal dataset, alterations in gene
expression between schizophrenia and control could not be
validated across chip platforms (Table 7). This indicates that
using this methodology, no technically robust disease-related
alterations could be detected in neurons from the schizophrenia
samples, in contrast to the endothelial cells.
In order to further characterise the disease signal in endothelial
cells, we investigated alterations in functional categories of genes, a
statistically more powerful approach than considering individual
gene changes. Numerous approaches to functional profiling of
gene expression data exist, which rely on different computational
approaches and assumptions. In the present study, we employed
two algorithms. The first, GSEA, looks for enrichment of genes in
a category at the top or bottom of a ranked list based on a
modified Kolmogorov-Smirnov statistic, and has been developed
specifically for the detection of biological differences which may be
modest relative to technical noise. The second, OntoExpress,
identifies categories of genes which are over or under represented
in a list of significant genes relative to their representation on the
entire chip. Some differences are expected due to the differences
between the algorithms [34], but a truly robust finding should be
detectable using either method.
62 categories were downregulated in schizophrenia endothelial
samples using GSEA and 33 using OntoExpress. The majority of
results were comparable regardless of the algorithm used (Table 8),
with a small number of exceptions: endothelial-specific and
developmental categories were only found significant with GSEA
and not OntoExpress, and categories relating to transcriptional
and translational processes were identified with OntoExpress but
not GSEA. No categories were significantly upregulated, which
reflects the bias towards downregulated genes seen in the data (not
shown).
Discussion
In the present study we show molecular alterations in the
vasculature of schizophrenia patients. Based on these data alone it
is not possible to infer whether alterations in RNA expression
reflect a functional impairment in the blood brain barrier.
Nonetheless, the results of gene expression profiling indicate a
downregulation of genes involved in ion transport, cell prolifer-
ation and adhesion, which are consistent with such an impairment.
Furthermore, downregulation of genes related to immune system
function was identified, including GO:0006954 ‘‘inflammatory
response’’ which was identified using both OntoExpress and
GSEA. Hanson and Gottesman have proposed inflammation of
the cerebral microvasculature as the source of blood-brain barrier
dysfunction in schizophrenia, with systemic effects [9]. However
the data from this study, and other studies from our laboratory on
T cell function in schizophrenia [35], point more towards a hypo-
inflammatory state in schizophrenic patients. This is consistent
with a growing body of evidence in the field, including the negative
association between schizophrenia and rheumatoid arthritis [36–
38], lower antibody reactions to vaccination [39], and decreased
Table 5. Results of cross platform validation of the cell type
comparison.
CODELINK DATA
Categories tested Enrichment score FDR q-value
AFFY_ENDO 1.63 0.001
AFFY_NEURON 21.32 0.148
AFFYMETRIX DATA
Categories tested Enrichment score FDR q-value
CL_ENDO 1.76 0.000
CL_NEURON 21.3 0.171
Based on the Affymetrix data, the 200 genes whose expression was the highest
in endothelial cells compared to neurons (AFFY_ENDO), and the 200 genes
whose expression was the highest in neurons compared to endothelial cells
(AFFY_NEURON) were used to create categories. These Affymetrix-derived
categories were then investigated in the ranked gene list (endothelial cells vs
neurons) generated using the Codelink platform. A positive enrichment score
indicates enrichment in endothelial cells, and a negative score indicates
enrichment in neurons. The categories were all found to be significantly
enriched in the predicted direction in the Codelink data (q,0.25). The converse
procedure was carried out testing categories generated from the Codelink data
(CL_ENDO, CL_NEURON) on the Affymetrix platform, with comparable results.
doi:10.1371/journal.pone.0003964.t005
Table 6. Results of cross platform validation of the
schizophrenia vs control comparison for endothelial cells.
CODELINK DATA
Categories tested Enrichment score FDR q-value
AFFY_UP (SZ) 1.5 0.013
AFFY_DOWN (C) 21.44 0.044
AFFYMETRIX DATA
Categories tested Enrichment score FDR q-value
CL_UP (SZ) 1.65 0.000
CL_DOWN (C) 21.69 0.000
Based on the Affymetrix data, the 200 genes whose expression was most
upregulated in schizophrenia (AFFY_UP), and the 200 genes whose expression
was the most downregulated in schizophrenia (AFFY_DOWN) were used to
create categories for analysis in the ranked list (schizophrenia vs control)
derived from the Codelink platform. A positive enrichment score indicates
enrichment in schizophrenia samples, and a negative enrichment score
indicates enrichment in control samples. These were all found to be
significantly enriched in the expected direction in the Codelink data (q,0.25).
The converse procedure was carried out testing categories generated from the
Codelink data (CL_UP, CL_DOWN) on the Affymetrix platform, with comparable
results.
doi:10.1371/journal.pone.0003964.t006
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schizophrenia has been positively linked to other auto-immune
disorders [41]. At the molecular level, increased levels of acute
phase proteins have been reported in schizophrenia pointing
towards a pro-inflammatory state [42,43], and conflicting data
exists on the role of inflammatory cytokines in the disorder [44]. A
potential explanation for these apparently opposing results is
overall dysregulation of inflammation, leading to an inappropriate
response (either too much or too little inflammation) depending on
the stimulus and site. Such a dysfunction in the blood brain barrier
is consistent with the broader implications of Hanson & Gottes-
man’s hypothesis, and could result in slower response and lower
resistance to brain injury/insult, affecting the regulation of supply
of substances to the brain. Furthermore, abnormal inflammatory
processes may have downstream effects on angiogenesis [45], and
thus may further impact vascular abnormalities. However,
conclusions cannot be firmly drawn without further in vivo study
of the microvasculature in schizophrenia patients.
The blood brain barrier is composed of endothelial cells,
pericytes, astrocyte end-feet and neuronal processes. A method for
isolating pure vascular endothelium has been developed [46];
however, as this method is specific for endothelial cells and
involves numerous steps, its use would preclude comparison of the
resulting cell population with neurons and other cell types.
Furthermore, cerebral microvascular function arises from the
interactions between its various components, therefore global data
for the intact microvessel is of greater interest. In this context, our
result of downregulation of genes in the GO category ‘‘spermato-
genesis’’ is of interest as numerous functional links exist between
the blood-brain barrier and the blood-testis barrier, including
shared properties of astrocytes and oligodendrocytes and the
Sertoli and Leydig cells of the testis [47], [48]. We speculate that
this result may indicate altered gene expression in non-endothelial
components of the blood-brain barrier. Interestingly, a recent
study has found a decreased number of oligodendrocytes per unit
length of capillary in post mortem prefrontal cortex from
schizophrenia patients [49] which provides a potential explanation
for some of the results seen here. Further investigation of these cell
types is clearly warranted.
Laser capture microdissection is a technically challenging
method due to the small amounts of tissue and the variability
that may be introduced at various stages of the analytical process,
compounded by the effects of working with post mortem human
tissue, and the present work involved extensive optimization and
validation of the methods prior to study commencement. In the
present study, although cell-type specific changes could be
detected in neurons, no schizophrenia-related alterations could
be reliably detected in neurons collected from the same brain
region as the endothelial cells (dorsolateral prefrontal cortex).
Although we (data not shown) and others [50–52] have found that
RNA amplification gives reproducible results, it does result in loss
and/or truncation of transcripts, leading to a smaller number of
high-quality arrays than would otherwise be expected, and
furthermore the final mRNA population analysed will not contain
the full range of information found in the original sample
[50,53,54]. Thus in this context the neuronal result cannot be
considered a true negative. Although no directly comparable study
has been carried out, there is much evidence for neuronal
alterations in schizophrenia at the molecular and structural level
[55], including data derived using similar methods in the same
[56,57] and other [2] brain regions. However, as the endothelial
data were collected in an identical manner, the results do provide
compelling preliminary evidence for molecular alterations in the
microvasculature of schizophrenia patients. More targeted and
functional studies of the blood-brain barrier, including investiga-
tion of its subcomponents, are now required, and further
investigation is necessary to determine whether, if proven, blood-
brain barrier dysfunction can directly explain the impairment in
glucose utilization in the brains of schizophrenic patients. The
potential effects of antipsychotic medication on the blood brain
barrier should also be assessed. Furthermore, investigation of other
cell types such as astrocytes, and further investigation of peripheral
tissues, is key to elucidating the role of metabolic abnormalities in
the pathophysiology of schizophrenia.
Supporting Information
Supplementary Information S1 A document containing
demographics variables for the cell type analysis, and additional
details of the microarray data processing
Found at: doi:10.1371/journal.pone.0003964.s001 (0.05 MB
DOC)
Figure S1 RNA 59 -39 signal bias. (a) RNA digestion plot
showing signal from probes decreases with distance of target
sequence from 39 end of transcript. Note the inter-chip variability
in the gradient of the curves. (b) The degree of RNA 59-39 signal
bias within a chip, as measured by the slope of RNA digestion
curve, displays strong positive correlation with the number of
probe-sets on the chip which are flagged as present.
Found at: doi:10.1371/journal.pone.0003964.s002 (7.00 MB TIF)
Figure S2 Detection and removal of RNA 5 -3signal bias from
Affymetrix GeneChip data on the expression profiles of endothe-
lial cells (E) and neurons (N). (a) PCA of RMA expression data
reveals that the major component of the variation in the data
Figure 4. Results of cross-platform validation of the schizophrenia vs control analysis for (a) endothelial cells and (b) neurons. The
figures were created by the GSEA software and plot the running enrichment score (ES) which reflects the degree to which a gene set is
overrepresented at the top or bottom of a ranked list of genes. The score at the peak of the plot (the score furthest from 0.0) is the ES for the gene
set. The position of individual members of the gene set in the ranked list is indicated by vertical lines.
doi:10.1371/journal.pone.0003964.g004
Table 7. Results of cross platform validation of the
schizophrenia vs control comparison for neurons.
CODELINK DATA
Categories tested Enrichment score FDR q-value
AFFY_UP (SZ) 0.77 0.734
AFFY_DOWN (C) 21.15 0.283
AFFYMETRIX DATA
Categories tested Enrichment score FDR q-value
CL_UP (SZ) 21.36 0.132
CL_DOWN (C) 21.69 0.589
The same procedure as described in Table 6 (endothelial cells) was carried out
on data from the neuronal samples. In only one of the four tests was the
category derived from one platform significantly enriched in the expected
direction on the other platform.
doi:10.1371/journal.pone.0003964.t007
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GSEA OntoExpress
GO ID Name Size FDR q value GO ID Name FDR q value
RESPONSE TO STIMULUS
GO0007606 sensory perception of chemical stimulus 105 0.060 GO:0007600 sensory perception 0.097
GO0007608 sensory perception of smell 86 0.114
GO0009581 detection of external stimulus 32 0.147
IMMUNE SYSTEM
GO0051240
positive regulation of organismal
physiological process 52 0.121 GO:0006952 defense response 0.028
GO0050867 positive regulation of cell activation 25 0.132 GO:0006955 immune response 0.038
GO0046651 lymphocyte proliferation 25 0.145 GO:0030154 cell differentiation 0.121
GO0050778 positive regulation of immune response 48 0.148
GO0046649 lymphocyte activation 82 0.149
GO0042113 B cell activation 32 0.150
GO0016066
cellular defense response (sensu
Vertebrata) 27 0.156
GO0050776 regulation of immune response 73 0.161
GO0050865 regulation of cell activation 40 0.164
GO0045321 immune cell activation 96 0.193
GO0030098 lymphocyte differentiation 34 0.199
GO0051249 regulation of lymphocyte activation 38 0.201
GO0001775 cell activation 97 0.202
GO0006959 humoral immune response 137 0.140
GO0016064
humoral defense mechanism (sensu
Vertebrata) 100 0.212
GO:0019735
antimicrobial humoral response (sensu
Vertebrata) 75 0.228
GO0019730 cytokine production 78 0.249
GO0009613 response to pest, pathogen or parasite 479 0.124 GO:0006954 inflammatory response 0.089
GO0009611 response to wounding 362 0.129
GO0006954 inflammatory response 198 0.132
GO0009605 response to external stimulus 460 0.146
GO0019882 antigen presentation 39 0.139
GO0030333 antigen processing 32 0.150
GO0045087 innate immune response 55 0.106
GO0042742 defense response to bacteria 53 0.117
GO0009615 response to virus 66 0.156 GO:0009615 response to virus 0.034
GO0006968 cellular defense response 93 0.174 GO:0006968 cellular defense response 0.065
FERTILIZATION
GO0007338 fertilization (sensu Metazoa) 35 0.158 GO:0007283 spermatogenesis 0.037
GO0009566 fertilization 36 0.161
MOTILITY
GO0051270 regulation of cell motility 28 0.144 GO:0006928 cell motility 0.097
GO0040012 regulation of locomotion 28 0.149 GO:0030155 regulation of cell adhesion 0.007
GO0030334 regulation of cell migration 28 0.153
GO:0016477 cell migration 95 0.226
GO0007610 behavior 175 0.137 GO:0010033
response to organic
substance 0.001
GO0042330 taxis 107 0.144
GO0007626 locomotory behavior 112 0.149
GO0006935 chemotaxis 107 0.155
GO:0042221 response to chemical stimulus 310 0.223
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GO ID Name Size FDR q value GO ID Name FDR q value
ION TRANSPORT
GO0030005 di-, tri-valent inorganic cation homeostasis 89 0.154 GO:0006811 ion transport 0.093
GO0006875 metal ion homeostasis 96 0.157 GO:0006810 transport 0.168
GO0030003 cation homeostasis 102 0.199
GO0006817 phosphate transport 76 0.196
NEGATIVE REGULATION OF CELL PROLIFERATION
GO0008285 negative regulation of cell proliferation 145 0.147 GO:0016049 cell growth 0.036
GO:0006915 apoptosis 0.066
DNA METABOLISM
GO0051052 regulation of DNA metabolism 31 0.161 GO:0006259 DNA metabolism 0.003
GO:0006281 DNA repair 0.043
PROTEIN MODIFICATION
GO0045860 positive regulation of protein kinase activity53 0.146 GO:0006464 protein modification 0.079
GO0045859 regulation of protein kinase activity 123 0.161
GO0043549 regulation of kinase activity 123 0.165
GO0051338 regulation of transferase activity 123 0.157
GO0000079
regulation of cyclin-dependent protein
kinase activity 38 0.167
GO0051347 positive regulation of transferase activity 53 0.150
ENDOTHELIAL-SPECIFIC
GO0001525 angiogenesis 61 0.246
GO0008217 blood pressure regulation 29 0.175
DEVELOPMENT
GO0007398 ectoderm development 85 0.119
GO0008544 epidermis development 77 0.144
GO0009888 tissue development 171 0.177
GO0007519 striated muscle development 38 0.148
GO0007517 muscle development 98 0.198
OTHER
GO0000270 peptidoglycan metabolism 26 0.129
PROTEIN ASSEMBLY/TRANSPORT
GO:0006461 protein complex assembly 0.094
GO:0006508 proteolysis and peptidolysis 0.100
GO:0015031 protein transport 0.077
GO:0006886 intracellular protein transport 0.196
SIGNAL TRANSDUCTION
GO:0007186
G-protein coupled receptor
protein signaling pathway 0.079
GO:0007165 signal transduction 0.006
TRANSCRIPTION/TRANSLATION
GO:0045449 regulation of transcription 0.032
GO:0006445 regulation of translation 0.043
GO:0008380 RNA splicing 0.063
GO:0006396 RNA processing 0.080
GO:0006260 DNA replication 0.195
GO:0006355
regulation of transcription,
DNA-dependent 0.197
GO:0006350 transcription 0.185
Gene function categories downregulated in endothelial cells from schizophrenia patients using GSEA (left side) and OntoExpress (right side). Related gene sets as
defined by GSEA leading edge analysis are grouped together in column 2, and categories are further grouped by theme. Equivalent categories (identical or closely
related in the Gene Ontology) identified by OntoExpress, are indicated in columns 5 and 6.
doi:10.1371/journal.pone.0003964.t008
Table 8. cont.
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cells and neurons. (b) PC1 of the RMA expression data shows
strong correlation with the RNA 5 -3signal bias within each chip.
The slope of a chip’s RNA digestion curve was used as the
measure of 5 -3signal bias. (c) Following a transformation to
remove 5 -3signal bias (see text for details), the major source of
variation in the data set is now differential gene expression
between the two cell types, which are now clearly separable on
PC1. (d) PC1 of transformed data is not correlated with the 5 -
3signal bias within a chip.
Found at: doi:10.1371/journal.pone.0003964.s003 (8.23 MB TIF)
Figure S3 Number of probesets on the Affymetrix GeneChip
detecting differential ex- pression between endothelial cells and
neurons at a range of false discovery rates (FDR), before and after
a correction was applied for 59-39 signal bias. For details of
systematic bias and correction, see text.
Found at: doi:10.1371/journal.pone.0003964.s004 (6.77 MB TIF)
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